Post Date: May 1, 2020
Seed investor CincyTech has announced the formation of Kurome Therapeutics (“Kurome”), a spin-off company based on cancer research discoveries made at Cincinnati Children’s by Daniel Starczynowski, PhD, and colleagues.
Kurome is developing combined IRAK1/4 and panFLT3 inhibitors to target cancer cells that evade the effects of chemotherapy drugs by adaptive resistance, having co-opted immune signaling pathways to survive.
Science Translational Medicine: Overcoming adaptive therapy resistance in AML by targeting immune response pathways
The Research Horizons blog features news and insights about the latest discoveries and innovations developed by the scientists of Cincinnati Children's. This blog does not provide medical advice, diagnosis, or treatment.